Rheumatology Network's Top 5: August 20, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2022.

Prevalence of Gout Reportedly Higher in Black Patients

Despite gout being largely associated with White men, new data suggest gout and hyperuricemia impart a larger burden on other demographic groups, including Black men, Black women, and White women.

Proton Pump Inhibitors Linked to Drug-Induced Lupus Erythematosus

Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.

FDA Approves Citrate-Free, High-Concentration Adalimumab Biosimilar Adalimumab-bwwd

Samsung Bioepis and Organon announced the US Food and Drug Administration (FDA) approval of the citrate-free, high-concentration (100 mg/mL) formulation of adalimumab-bwwd (HADLIMA), a biosimilar of adalimumab (HUMIRA), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and Crohn’s disease.

Psoriatic Arthritis Remission Strongly Associated with Alleviation of Psoriasis Symptoms

“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”

Low Serum Urate Associated with Weight Loss, Sarcopenia

“These observations suggest that the often-observed epidemiologic correlation between low serum urate and adverse health outcomes may be confounded."